<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36479634</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0496</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pediatric pulmonology</Title><ISOAbbreviation>Pediatr Pulmonol</ISOAbbreviation></Journal><ArticleTitle>Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis.</ArticleTitle><Pagination><StartPage>871</StartPage><EndPage>877</EndPage><MedlinePgn>871-877</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.26267</ELocationID><Abstract><AbstractText Label="BACKGROUND">Viral respiratory infections trigger pulmonary exacerbations (PEs) in children with cystic fibrosis (CF), but their clinical impact is not well understood.</AbstractText><AbstractText Label="METHODS">A retrospective review of pediatric patients with CF who underwent nasopharyngeal respiratory viral panel&#xa0;testing during hospitalization for a PE between 2011 and 2018 was conducted. Patients were dichotomized into viral-positive and viral-negative groups. The results of spirometry, respiratory cultures, duration of hospitalization, and risk for subsequent PEs were analyzed.</AbstractText><AbstractText Label="RESULTS">Ninety-five patients had 210 hospitalizations for PE (viral-positive&#x2009;=&#x2009;71/210, 34%) during the study period. Rhinovirus/enterovirus was the most common virus (52/71, 73%) identified. Viral-positive patients were younger (p&#x2009;&lt;&#x2009;0.001), had higher baseline forced expiratory volume in 1&#x2009;s&#xa0;(FEV1) (p&#x2009;=&#x2009;0.037), continued to maintain higher FEV1 at 3 and 6 months following PE (p&#x2009;=&#x2009;0.003 and 0.002, respectively), and had a shorter duration of hospitalization (p&#x2009;=&#x2009;0.006) compared to the viral-negative group. There was no difference between the two groups in the rate of recovery of FEV1 at 3 and 6 months following PE (p&#x2009;=&#x2009;0.71 and 0.405, respectively), time to the next PE (hazard ratio&#x2009;=&#x2009;1.34, p&#x2009;=&#x2009;0.157), number of subsequent PEs in 6 months (p&#x2009;=&#x2009;0.99), or Pseudomonas aeruginosa&#xa0;(PA) acquisition (p&#x2009;=&#x2009;0.707).</AbstractText><AbstractText Label="CONCLUSIONS">In this single pediatric CF center cohort, one-third of PEs requiring hospitalization were associated with a viral infection, with rhinovirus/enterovirus being the most common. Viral-positive PEs were not associated with a greater decline or delayed recovery of lung function, increased risk for PA acquisition, shortened duration to next PE, longer hospital stay, or an increase in the frequency of subsequent PEs in 6 months compared to viral-negative PEs.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez-Rosales</LastName><ForeName>Noel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Children's Healthcare of Atlanta, Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasi</LastName><ForeName>Ajay S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-0435-2807</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics and Children's Healthcare of Atlanta, Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCracken</LastName><ForeName>Courtney E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Pediatric Biostatistics Core, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>George L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Children's Healthcare of Atlanta, Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starks</LastName><ForeName>Miah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Children's Healthcare of Atlanta and Emory University Cystic Fibrosis Care Center, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stecenko</LastName><ForeName>Arlene</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Children's Healthcare of Atlanta, Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guglani</LastName><ForeName>Lokesh</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8145-0430</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics and Children's Healthcare of Atlanta, Center for Cystic Fibrosis and Airways Disease Research, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Pulmonol</MedlineTA><NlmUniqueID>8510590</NlmUniqueID><ISSNLinking>1099-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003550" MajorTopicYN="Y">Cystic Fibrosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005541" MajorTopicYN="N">Forced Expiratory Volume</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011552" MajorTopicYN="Y">Pseudomonas Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pseudomonas aeruginosa</Keyword><Keyword MajorTopicYN="N">cystic fibrosis</Keyword><Keyword MajorTopicYN="N">lung function</Keyword><Keyword MajorTopicYN="N">pulmonary exacerbation</Keyword><Keyword MajorTopicYN="N">viral infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>8</Day><Hour>14</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36479634</ArticleId><ArticleId IdType="doi">10.1002/ppul.26267</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Dickinson KM, Collaco JM. Cystic fibrosis. Pediatr Rev. 2021;42(2):55-67.</Citation></Reference><Reference><Citation>Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J. 2012;40(1):61-66.</Citation></Reference><Reference><Citation>Sanders DB, Bittner RCL, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182(5):627-632.</Citation></Reference><Reference><Citation>Wark PAB, Tooze M, Cheese L, et al. Viral infections trigger exacerbations of cystic fibrosis in adults and children. Eur Respir J. 2012;40(2):510-512.</Citation></Reference><Reference><Citation>Hizal M, Yalcin E, Alp A, et al. Respiratory viruses: what is their role in acute exacerbations in children with cystic fibrosis? Pediatr Pulmonol. 2020;55(7):1646-1652.</Citation></Reference><Reference><Citation>Asner S, Waters V, Solomon M, et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. Journal of Cystic Fibrosis. 2012;11(5):433-439.</Citation></Reference><Reference><Citation>Waters V, Ratjen F. Pulmonary exacerbations in children with cystic fibrosis. Ann Am Thorac Soc. 2015;12:S200-S206.</Citation></Reference><Reference><Citation>Ramsey BW. The effect of respiratory viral infections on patients with cystic fibrosis. Arch Pediatr Adolesc Med. 1989;143(6):662-668.</Citation></Reference><Reference><Citation>Brestovac B, Lawrence C, Speers DJ, Sammels LM, Mulrennan S. Respiratory viral infections in Western Australians with cystic fibrosis. Respir Med. 2020;161:105854.</Citation></Reference><Reference><Citation>Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999;103(3):619-626.</Citation></Reference><Reference><Citation>Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. 1995;73(2):117-120.</Citation></Reference><Reference><Citation>Cousin M, Molinari N, Foulongne V, et al. Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis. Influenza Other Respir Viruses. 2016;10(2):109-112.</Citation></Reference><Reference><Citation>Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808.</Citation></Reference><Reference><Citation>Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324-1343.</Citation></Reference><Reference><Citation>Miller MR, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.</Citation></Reference><Reference><Citation>Esther CR, Lin F-C, Kerr A, Miller MB, Gilligan PH. Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol. 2014;49(9):926-931.</Citation></Reference><Reference><Citation>Etherington C, Naseer R, Conway SP, Whitaker P, Denton M, Peckham DG. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J&#xa0;Cyst&#xa0;Fibros. 2014;13(1):49-55.</Citation></Reference><Reference><Citation>Esposito S, Dacc&#xf2; V, Daleno C, et al. Human rhinovirus infection in children with cystic fibrosis. Jpn J Infect Dis. 2014;67(5):399-401.</Citation></Reference><Reference><Citation>Deschamp AR, Hatch JE, Slaven JE, et al. Early respiratory viral infections in infants with cystic fibrosis. J&#xa0;Cyst&#xa0;Fibros. 2019;18(6):844-850.</Citation></Reference><Reference><Citation>Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. 1998;26(6):371-379.</Citation></Reference><Reference><Citation>Chin M, De Zoysa M, Slinger R, et al. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations. J&#xa0;Cyst&#xa0;Fibros. 2015;14(4):482-489.</Citation></Reference><Reference><Citation>Flight WG, Bright-Thomas RJ, Tilston P, et al. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax. 2014;69(3):247-253.</Citation></Reference><Reference><Citation>Gulla KM, Balaji A, Mukherjee A, et al. Course of illness after viral infection in Indian children with cystic fibrosis. J Trop Pediatr. 2019;65(2):176-182.</Citation></Reference><Reference><Citation>Zheng S, De BP, Choudhary S, et al. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity. 2003;18(5):619-630.</Citation></Reference><Reference><Citation>Block JK, Vandemheen KL, Tullis E, et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 2006;61(11):969-974.</Citation></Reference><Reference><Citation>Kiedrowski MR, Bomberger JM. Viral-bacterial co-infections in the cystic fibrosis respiratory tract. Front Immunol. 2018;9:3067.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>